glp-1/gip vs glp-1 & GIP Agonists | Obesity and Diabetes Management | Harrison's updates (22nd Ed.) glp-1/gip vs glp-1 Emerging Role

It is the first once-weekly injectable formulation approved by the FDA for the treatment of T2D (January 2012)

August 2023: Jaclyn Bjorklund, 2:23-cv-01020-JDC-KK, became one of the first people to file an Ozempic and Mounjaro gastroparesis lawsuit

This flexibility helps it appeal to a broader audience, from regular gym-goers to individuals focused more on general mobility and functional strength

Diabetes is a growing concern in the United States, with 35 million individuals impacted by type 2 diabetes mellitus (T2DM).[1] This chronic condition can lead to other health complications

J Med Soc (2017) 31:185

A nephrologist perspective on obesity: from kidney injury to clinical management